109 related articles for article (PubMed ID: 29104118)
1. Clinical trial conduct in special populations and developing regions: An overview of the DOVE study in pediatric patients with sickle cell disease.
Reams SG; Messana L; Brown PB; Nanry K; Gunnell AE
Contemp Clin Trials; 2018 Jan; 64():88-94. PubMed ID: 29104118
[TBL] [Abstract][Full Text] [Related]
2. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Hoppe CC; Styles L; Heath LE; Zhou C; Jakubowski JA; Winters KJ; Brown PB; Rees DC; Heeney MM
Pediatr Blood Cancer; 2016 Feb; 63(2):299-305. PubMed ID: 26402148
[TBL] [Abstract][Full Text] [Related]
3. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
Heeney MM; Hoppe CC; Abboud MR; Inusa B; Kanter J; Ogutu B; Brown PB; Heath LE; Jakubowski JA; Zhou C; Zamoryakhin D; Agbenyega T; Colombatti R; Hassab HM; Nduba VN; Oyieko JN; Robitaille N; Segbefia CI; Rees DC;
N Engl J Med; 2016 Feb; 374(7):625-35. PubMed ID: 26644172
[TBL] [Abstract][Full Text] [Related]
4. Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia.
Jakubowski JA; Hoppe CC; Zhou C; Smith BE; Brown PB; Heath LE; Inusa B; Rees DC; Small DS; Gupta N; Yao S; Heeney M; Kanter J
Thromb Haemost; 2017 Feb; 117(3):580-588. PubMed ID: 27929203
[TBL] [Abstract][Full Text] [Related]
5. Prasugrel hydrochloride for the treatment of sickle cell disease.
Conran N; Rees DC
Expert Opin Investig Drugs; 2017 Jul; 26(7):865-872. PubMed ID: 28562105
[TBL] [Abstract][Full Text] [Related]
6. Prasugrel for Sickle Cell Vaso-Occlusive Events.
Badawy SM
N Engl J Med; 2016 Jul; 375(2):185. PubMed ID: 27410931
[No Abstract] [Full Text] [Related]
7. Prasugrel for Sickle Cell Vaso-Occlusive Events.
Heeney MM; Hoppe CC; Rees DC
N Engl J Med; 2016 Jul; 375(2):185-6. PubMed ID: 27410930
[No Abstract] [Full Text] [Related]
8. Population Pharmacokinetic and Exposure-Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia.
Moser BA; LaBell ES; Chigutsa E; Jakubowski JA; Small DS
Clin Pharmacokinet; 2018 Feb; 57(2):243-254. PubMed ID: 28578536
[TBL] [Abstract][Full Text] [Related]
9. Addressing challenges of clinical trials in acute pain: The Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study.
Nottage KA; Hankins JS; Faughnan LG; James DM; Richardson J; Christensen R; Kang G; Smeltzer M; Cancio MI; Wang WC; Anghelescu DL
Clin Trials; 2016 Aug; 13(4):409-16. PubMed ID: 27000103
[TBL] [Abstract][Full Text] [Related]
10. Using the consolidated framework for implementation research to identify recruitment barriers and targeted strategies for a shared decision-making randomized clinical trial in pediatric sickle cell disease.
Strong H; Hood AM; Johnson Y; Hackworth R; Reed-Shackelford M; Ramaswamy R; Varughese T; Quinn CT; Crosby LE
Clin Trials; 2023 Jun; 20(3):211-222. PubMed ID: 36794731
[TBL] [Abstract][Full Text] [Related]
11. Successful utilization of an electronic pain diary in a multinational phase 3 interventional study of pediatric sickle cell anemia.
Heath LE; Heeney MM; Hoppe CC; Adjei S; Agbenyega T; Badr M; Masera N; Zhou C; Brown PB; Jakubowski JA; Dampier C
Clin Trials; 2017 Dec; 14(6):563-571. PubMed ID: 28743191
[TBL] [Abstract][Full Text] [Related]
12. Prasugrel in children with sickle cell disease: pharmacokinetic and pharmacodynamic data from an open-label, adaptive-design, dose-ranging study.
Styles L; Heiselman D; Heath LE; Moser BA; Small DS; Jakubowski JA; Zhou C; Redding-Lallinger R; Heeney MM; Quinn CT; Rana SR; Kanter J; Winters KJ
J Pediatr Hematol Oncol; 2015 Jan; 37(1):1-9. PubMed ID: 25493452
[TBL] [Abstract][Full Text] [Related]
13. Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel.
Ohno K; Tanaka H; Samata N; Jakubowski JA; Tomizawa A; Mizuno M; Sugidachi A
Thromb Res; 2014 Oct; 134(4):889-94. PubMed ID: 25130912
[TBL] [Abstract][Full Text] [Related]
14. Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial.
Chin CT; Neely B; Magnus Ohman E; Armstrong PW; Corbalán R; White HD; Prabhakaran D; Winters KJ; Fox KA; Roe MT;
Stroke; 2016 Apr; 47(4):1135-9. PubMed ID: 26883498
[TBL] [Abstract][Full Text] [Related]
15. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.
Roe MT; Cyr DD; Eckart D; Schulte PJ; Morse MA; Blackwell KL; Ready NE; Zafar SY; Beaven AW; Strickler JH; Onken JE; Winters KJ; Houterloot L; Zamoryakhin D; Wiviott SD; White HD; Prabhakaran D; Fox KA; Armstrong PW; Ohman EM;
Eur Heart J; 2016 Jan; 37(4):412-22. PubMed ID: 26637834
[TBL] [Abstract][Full Text] [Related]
16. Clinical Trial Educator program - a novel approach to accelerate enrollment in a phase III International Acute Coronary Syndrome Trial.
Kendall B; Städeli R; Schegg B; Olbrich M; Chen E; Harmelin-Kadouri R; Aurup P; Schwab T; Hildemann SK
Clin Trials; 2012 Jun; 9(3):358-66. PubMed ID: 22426648
[TBL] [Abstract][Full Text] [Related]
17. Treatment for children with severe aplastic anemia and sickle cell disease in low income countries in Latin America: a report on the recent meetings of the Monza International School of Pediatric Hematology/Oncology (MISPHO): Part III.
Howard SC; Wilimas JA; Flores A; Pacheco C; de Reyes G; Machin S; Svarch E; Navarrete M; Nieves R; Rodriguez H; Masera G;
Pediatr Blood Cancer; 2007 May; 48(5):598-9. PubMed ID: 16883599
[TBL] [Abstract][Full Text] [Related]
18. [The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses].
Abaci A
Turk Kardiyol Dern Ars; 2015 Oct; 43 Suppl 2():1-6. PubMed ID: 27326444
[TBL] [Abstract][Full Text] [Related]
19. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
[TBL] [Abstract][Full Text] [Related]
20. Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study.
Inusa BPD; Colombatti R; Rees DC; Heeney MM; Hoppe CC; Ogutu B; Hassab HM; Zhou C; Yao S; Brown PB; Heath LE; Jakubowski JA; Abboud MR
J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31744266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
